fibronectin type III domain containing 3AGenealiases: FNDC3 · HUGO · bA203I16.1 · bA203I16.5
Q-omics provides the consensus-scored FNDC3A profile across patient tissues and cancer cell-line models. FNDC3A expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FNDC3A is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, FNDC3A RNA expression shows 21,541 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KICH, and THYM as cancer lineages where FNDC3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNDC3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNDC3A survival associations across molecular data types. FNDC3A RNA expression shows survival associations in the most cancer types (30), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNDC3A RNA expression–survival associations across cancer types. High FNDC3A expression shows unfavorable associations in CESC, LUSC, UVM and MESO, but favorable associations in KIRC and UCEC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FNDC3A RNA expression.
This table summarizes FNDC3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FNDC3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNDC3A shows lower tumor expression in KICH, LUSC, THCA and BRCA and higher tumor expression in HNSC and STAD. The KICH box plot shows higher FNDC3A RNA expression in normal versus tumor tissue (log2 FC = −1.732, t-test p < 0.001).
This table shows molecular features associated with FNDC3A in patient tissues and cancer cell lines. In patient samples, FNDC3A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FNDC3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
